• SciSparc unit NeuroThera Labs initiated a Phase IIb clinical trial site at Hannover Medical School for SCI-110 in adult Tourette syndrome.
• SCI-110 combines dronabinol with palmitoylethanolamide in one oral dosage form, targeting tic reduction with fewer side effects.
• Study design: randomized, double-blind, placebo-controlled cross-over; primary endpoint is Yale Global Tic Severity Scale change at weeks 12, 26.
• Phase IIa results cited an average 21% tic reduction across participants, supporting progression into the Phase IIb program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150841PRIMZONEFULLFEED9762664) on July 15, 2026, and is solely responsible for the information contained therein.